FAQ · 22 TRACKS
CJC-1295: Frequently Asked Questions
Direct answers from the published CJC-1295 record — definitional, mechanistic, dose-context, safety, and regulatory — each answer cited where it makes a quantitative claim.
What is CJC-1295?
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), built on the hGRF(1-29) fragment with four protease-resistant substitutions. The DAC variant adds covalent binding to serum albumin, giving it a multi-day half-life [1]; the no-DAC form, Modified GRF 1-29, keeps the substitutions but is short-acting. It is a single research peptide, not a blend.
What is CJC-1295 DAC?
CJC-1295 DAC is the 'Drug Affinity Complex' variant: a maleimidopropionyl linker lets the peptide covalently bind the Cys34 thiol of circulating serum albumin, extending its plasma half-life toward that of albumin itself — an estimated 5.8 to 8.1 days in healthy adults [1]. The albumin tether is the difference between a minutes-scale peptide and a multi-day one.
How does CJC-1295 work at the molecular level?
CJC-1295 binds the GHRH receptor, a class B G-protein-coupled receptor, on pituitary somatotrophs, activating Gs/cAMP/PKA signaling that drives GH gene transcription and pulsatile GH release, which in turn raises hepatic IGF-1. Cryo-EM work has resolved how peptide agonists engage and activate this receptor [7]. The receptor step is the same one native GHRH uses.
Does CJC-1295 preserve the natural pulse pattern of growth hormone?
Yes. In healthy men, a single 60 or 90 micrograms/kg dose raised basal GH about 7.5-fold and mean GH and IGF-1 by roughly 45% a week later, while the frequency and magnitude of pulsatile GH secretion were unaltered — pulsatility persisted under continuous GHRH-analog stimulation [3]. That is what separates a secretagogue from a direct GH injection.
What does CJC-1295 do?
In published studies, CJC-1295 produces dose-dependent, sustained elevations of growth hormone and IGF-1. In a GHRH-knockout mouse, 2 micrograms once every 24 hours fully normalized GH-axis-dependent growth and raised pituitary GH mRNA [4]. In healthy adults, single doses elevated GH for six-plus days and IGF-1 for nine to eleven days [1].
Is CJC-1295 safe?
CJC-1295 is an unapproved research chemical with only limited early human pharmacokinetic data. Theoretical concerns include fluid retention, effects on insulin sensitivity, and epidemiologic links between higher IGF-1 and certain cancers; FDA briefing materials for the 2024 compounding advisory committee cited immunogenicity concerns [1]. There is no long-term human safety data.
How much CJC-1295 should I take?
This site does not recommend doses for any person. The published research used single subcutaneous doses of 30, 60, or 90 micrograms/kg in human PK studies [1] [3], and 2 micrograms per dose in a mouse study [4]. These are doses administered in studies, not human-use recommendations, and CJC-1295 is unapproved.
How much CJC-1295 DAC should I take?
No controlled trial establishes a human-use dose for CJC-1295 DAC. The human PK studies that characterized its kinetics used 30 to 90 micrograms/kg subcutaneously [1] [3], and the long half-life means exposure persists for days after a single dose. The studies describe what was administered to volunteers, not guidance for anyone.
What is CJC-1295 with DAC?
CJC-1295 with DAC is the same tetrasubstituted GHRH(1-29) peptide plus the albumin-binding DAC moiety, which is what converts it from a short-acting peptide into a multi-day-acting one [1]. The DAC handle covalently bonds to serum albumin; remove it and you have the short-acting no-DAC form instead.
How to reconstitute CJC-1295?
CJC-1295 is supplied as a lyophilized peptide; in research handling it is reconstituted with bacteriostatic water and refrigerated. Oral bioavailability is negligible, so the studied route is injection, not ingestion. This describes laboratory handling of a research reagent, not human use.
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog — a growth-hormone secretagogue — not an anabolic-androgenic steroid. It works upstream by prompting the pituitary to release the body's own growth hormone through the GHRH receptor [7], rather than acting as a hormone itself at androgen receptors.
Where to inject CJC-1295?
The route used in studies is subcutaneous injection; early GRF(1-29) pharmacokinetic work also used intravenous administration [1]. This is a description of study methodology, not a human-use instruction. Oral routes are not studied because the peptide has negligible oral bioavailability.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA or any major regulator for human use. It was reviewed by the 2024 FDA Pharmacy Compounding Advisory Committee and was not recommended for, and is not on, the 503A compounding bulks list [1]. It is sold and handled as a research chemical.
How much CJC-1295 / ipamorelin should I take?
Community protocols often cite fixed microgram doses for the CJC-1295/ipamorelin pairing, but these are not derived from controlled human trials. The published CJC-1295 PK data used 30 to 90 micrograms/kg of the GHRH analog alone [1] [3]; no controlled study sets a dose for the combination, and this site recommends none.
Does CJC-1295 and ipamorelin work?
The mechanistic rationale is sound: combining a GHRH analog (CJC-1295) with a GHRP (ipamorelin) drives GH release greater than either alone, because they act through distinct receptors. Controlled human efficacy data for the specific combination in healthy adults remain limited; the rationale is established, the controlled trials are not [3].
What is CJC-1295 ipamorelin?
CJC-1295 ipamorelin refers to a research combination pairing the GHRH analog CJC-1295 with the selective GH secretagogue ipamorelin. The two act through distinct receptors — the GHRH receptor and the ghrelin/GHS receptor — and GHRH+GHRP co-administration produces GH release greater than either agent alone. It is a research pairing, not a validated regimen.
Are CJC-1295 peptides safe?
CJC-1295 is an unapproved research chemical; published human safety data are limited to small early-phase PK studies [1] [3]. Theoretical concerns include fluid retention, insulin-sensitivity effects, and IGF-1-related cancer-risk epidemiology, plus FDA-noted immunogenicity concerns. No long-term human safety record exists.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis, and the published literature does not establish a direct effect on testosterone in healthy adults [1]. Claims either way circulate online without controlled-trial support. The studied readouts are GH and IGF-1, not sex hormones.
What are the side effects of CJC-1295?
Reported and theoretical concerns from GH-axis stimulation include fluid retention and edema, driven by GH-related sodium reabsorption, and effects on insulin sensitivity; sustained IGF-1 elevation is the basis for cancer-risk caution. Human safety data on CJC-1295 itself are limited to early-phase studies [1] [3].
What to expect when taking CJC-1295?
In studies, CJC-1295 produced sustained, dose-dependent rises in GH and IGF-1 over days; the no-DAC form acts only briefly [1]. This describes measured research outcomes, not a human-use expectation, because CJC-1295 is unapproved and untested in long-term human trials. The site reports what was measured, not what to anticipate.
Does CJC-1295 lower testosterone?
There is no controlled human evidence that CJC-1295 lowers testosterone. It operates on the GH/IGF-1 axis rather than suppressing the hypothalamic-pituitary-gonadal axis the way some hormones do [1]. The published studies tracked GH and IGF-1, and did not report testosterone suppression.
Are peptides safer than TRT?
This is not answerable from the CJC-1295 literature. GHRH analogs and testosterone therapy act on entirely different axes, and unlike testosterone therapy, CJC-1295 has no approved indication and no long-term human safety data to compare against [1]. A safety comparison requires data the CJC-1295 record does not contain.